BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
03 April 2019 - 5:58AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced a clinical trial collaboration and supply
agreement (the “Agreement”) with Incyte (NASDAQ:INCY), a
global biopharmaceutical company focused on discovering and
developing novel therapeutics in oncology and other serious
diseases.
The Agreement is focused on, but not limited to,
the selection of novel combinations for the treatment of advanced
breast cancer along with a planned clinical study of BriaCell’s
lead candidate, Bria-IMT™, with Incyte’s selected compounds for
advanced breast cancer.
Under the terms of the Agreement,
BriaCell will evaluate combinations of novel therapeutics for the
treatment of patients with advanced breast cancer. Incyte will
provide BriaCell with selected novel compounds to be used in the
planned combination study with Bria-IMT™.
"It is our belief that checkpoint inhibitors may
significantly amplify the tumor-reducing effects of BriaCell’s
novel immunotherapy, Bria-IMT™, in advanced breast cancer patients.
Incyte’s portfolio has several candidates, including an
anti-PD-1 monoclonal antibody and an IDO1 inhibitor, that we
hope will improve the clinical benefits of Bria-IMT™," stated Dr.
Bill Williams, BriaCell’s President and Chief Executive Officer.
"Incyte is a world-class biopharmaceutical company, we are aligned
with the value that the team there places on innovation and we look
forward to working with Incyte’s scientists and clinical experts to
develop novel therapeutics for advanced breast cancer
patients.”
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, its lead candidate, in a combination
study with pembrolizumab [KEYTRUDA®; manufactured by Merck &
Co., Inc. (NYSE: MRK)]. The combination study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: Farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024